Eye On Delta, Sanofi/GSK To Begin India Trials Of COVID-19 Vaccine
Pfizer/BioNTech Look At Booster Shots
Sanofi and GSK, which are in the middle of Phase III global trials for their COVID-19 vaccine candidate, plan to test the contender against all variants of concern including the highly contagious Delta variant, Scrip has learned. Meanwhile, Pfizer/BioNTech is looking at a booster to combat lower efficacy/effectiveness against this variant.
You may also be interested in...
Sanofi and GSK are way behind in the COVID-19 vaccine race and the start of a rolling review of Vizprevtyn at the European Medicines Agency is an important step.
Japan has granted an emergency approval to Chugai/Roche/Regeneron's antibody cocktail after a rapid review, while India has emerged as one of the top purchasers globally of COVID-19 vaccines as it looks to protect more of its population.
Studies point to Johnson & Johnson, Pfizer and Bharat Biotech’s vaccines neutralizing the Delta variant of SARS-CoV-2, even if efficacy is lower compared to the original strain. This follows positive news from other vaccine companies but will the Lambda variant cause a setback?